Mirum Pharmaceuticals has been granted a patent for a method to treat cholestasis in liver disease patients by administering an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) at a dose of at least 10 µg/kg/day. Another claim involves treating cholestatic pruritus in Alagille Syndrome patients with maralixibat at a specific dosage range. GlobalData’s report on Mirum Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mirum Pharmaceuticals, Molecular diagnosis biomarkers was a key innovation area identified from patents. Mirum Pharmaceuticals's grant share as of April 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cholestatic pruritus in alagille syndrome with maralixibat
A recently granted patent (Publication Number: US11918578B2) discloses a method for treating cholestatic pruritus in individuals with Alagille Syndrome (ALGS) by administering maralixibat in specific dosages. The method involves administering maralixibat in a liquid pharmaceutical composition ranging from about 0.001 mg/mL to about 16 mg/mL, at a dosage of about 400 µg/kg/day to about 800 µg/kg/day. The administration of maralixibat is specified to be once daily, with variations in dosage and duration of treatment mentioned in the claims.
Furthermore, the patent claims specify that the treatment with maralixibat can be extended for at least 18 weeks, 2 years, or even 3 years. The method is particularly applicable to pediatric subjects aged at least 1 year and involves oral administration of the liquid pharmaceutical composition, which may contain about 10 mg/mL of maralixibat. The composition is described as an oral solution, specifically an aqueous solution, and is recommended to be administered prior to food ingestion. These claims provide a detailed outline of the method for effectively managing cholestatic pruritus in ALGS patients using maralixibat, highlighting specific dosages, administration routes, and treatment durations for optimal therapeutic outcomes.
To know more about GlobalData’s detailed insights on Mirum Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
